Ocugen Inc. (NASDAQ:OCGN) is one of the 10 best penny stocks that could triple your money. On March 24, Ocugen Inc.

In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA ...

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Ocugen’s updated fair value estimate has shifted from US$10.36 to US$11.57, putting recent analyst work into a slightly higher price target range. Analysts are tying this move to fresh research around ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

German company Complement Therapeutics, which has a research laboratory at Stevenage Bioscience Catalyst, reports that the ...

Ocugen Inc. (NASDAQ:OCGN) shares fell 5% Tuesday following the announcement of 12-month data from its Phase 2 ArMaDa clinical ...

GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMDCTx001 is an investigational ...

Ocugen Inc. OCGN shares are down during Tuesday’s session following topline data from its Phase 2 ArMaDa trial of OCU410.